Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 964–965 | Cite as

ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma

  • Lucas GoenseEmail author
  • Steven H. LinEmail author
Open Access
ASO Author Reflections
  • 100 Downloads

Past

Surgical resection of the esophagus combined with neoadjuvant chemoradiotherapy (trimodality therapy) is a generally recommended treatment strategy with curative intent for patients with non-metastasized esophageal cancer.1 However, even after trimodality therapy, 5-year overall survival remains relatively poor (36–47%), which is mainly attributable to the high incidence (49–85%) of disease recurrence after surgery.1 As such, in the group of patients who experience early disease recurrence within 1 year of completing their treatment, the benefit of surgery probably does not outweigh its potential side effects.2 Some suggest that consideration should therefore be given to forgo surgery in patients who are likely to have early disease recurrence after surgery. To guide treatment decision making, this study aimed to develop a preoperative prediction model to identify patients at high risk of early disease recurrence after trimodality therapy for esophageal adenocarcinoma.

Present

The current study identified gender, poor tumor differentiation grade, signet ring cell adenocarcinoma, baseline clinical nodal status, and SUVmax of the initial positron emission tomography/computed tomography as independent prognostic factors for early recurrence after trimodality therapy.3 Based on the subsequent prediction model, patients at high-risk of early recurrence had no survival benefit of trimodality therapy compared with definitive chemoradiotherapy. This finding suggests that, indeed, a group of patients with clinically operable disease may not benefit from an esophageal resection after chemoradiotherapy.

Future

An important caveat of this prediction model based on clinicopathological characteristics is that it is not 100% accurate. As such, avoiding surgery based on its predictions may cause the very undesirably result of a missed opportunity for cure in patients with locoregional disease only. Further improvement in prognostication is desired to accurately stratify patients by potential benefit of surgery balanced with risk of occult distant metastases. In this context, quantification of circulating tumor DNA represents a novel approach for disease burden quantification that has the potential to complement prognostication in esophageal cancer. Furthermore, recent studies have shown that functional magnetic resonance imaging4 and cancer stem-cell molecules5 hold considerable promise for improving the accuracy of prognosis. Future improvement of the current model with these novel predictors will likely improve prognostication, and therewith support choices of care and shared decision making in the treatment of patients with esophageal cancer.

Notes

Disclosures

Lucas Goense and Steven H. Lin have no conflicts of interest to disclose.

References

  1. 1.
    van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–2084.CrossRefGoogle Scholar
  2. 2.
    Lagergren P, Avery KNL, Hughes R, et al. Health-related quality of life among patients cured by surgery for esophageal cancer. Cancer. 2007;110:686–693.CrossRefGoogle Scholar
  3. 3.
    Goense L, van Rossum PSN, Xi M, et al. Preoperative nomogram to risk stratify patients for the benefit of trimodality therapy in esophageal adenocarcinoma. Ann Surg Oncol. 2018;25:1598–1607.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Heethuis SE, Goense L, van Rossum PSN, et al. DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer. Acta Oncol. 2018;57:1201–1208.CrossRefGoogle Scholar
  5. 5.
    Song S, Xie M, Scott AW, et al. A novel YAP1 inhibitor targets CSC-enriched radiation-resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma. Mol Cancer Ther. 2018;17:443–454.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Medical Center UtrechtUtrechtThe Netherlands
  2. 2.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations